The proceeds will be used for the construction and expansion of R&D and production sites.
AstaTech recently completed a Series B financing round valued at CNY 200 million (USD 29.6 billion).
This round was led by Shenyin&Wanguo Investment (Chinese: 申银万国). Gree Investment (Chinese: 格力金投), Guanghua Wutong (Chinese: 光华梧桐), Kangju Venture Capital (Chinese: 康居创投), Mingcheng Ruiying (Chinese: 明诚瑞鹰) and Chengdu Daopu (Chinese: 成都道璞) also participated in this deal.
The funding will be mainly used for the expansion and upgrading of the R&D facility in Wenjiang and the construction of manufacturing sites at Yibin, Jinchang and Guangan.
Founded in 2005, AstaTech is dedicated to CRO, CDMO, CMO, CMC and Process Safety Evaluation services for global pharmaceutical companies in small molecule drug intermediates.
Other players who include Easton Biopharmaceutical (Chinese: 苑东生物)，dMed (Chinese: 缔脉生物医药) and Tigermed (Chinese: 泰格医药).